<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00824044</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000838</org_study_id>
    <nct_id>NCT00824044</nct_id>
  </id_info>
  <brief_title>Quantitative Electroencephalogram (QEEG) Predictors of Response to Psychotherapy Versus Antidepressant Treatment in Depression</brief_title>
  <official_title>QEEG Predictors of Response for Psychotherapy Compared to Pharmacotherapy in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out if a test can predict whether someone with
      depression will get better with treatment. We also want to find out whether there are changes
      in the brains of depressed patients having different types of treatment (drug therapy vs.
      talk therapy). We hope that a test called QEEG (Quantitative Electroencephalogram) can tell
      us if a treatment is going to work, even before the person starts to feel better.

      Hypothesis 1: Response to treatment will correlate with changes in QEEG metrics.

      Hypothesis 2: QEEG parameters, different from those that predict response to pharmacotherapy,
      will be associated with response to CBT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To our knowledge, QEEG has not been studied in the prediction of response to CBT, an
      important and widely used non-pharmacologic approach to treating depression. Establishing
      QEEG technology as a predictor of response to CBT could help to guide treatment selection for
      individual patients. It is probable that certain patient populations are more likely to
      respond to either psychotherapeutic or psychopharmacological interventions, while others may
      benefit from a combination of treatment modalities. This study will provide preliminary
      information about the utility of QEEG as a predictor of response in psychotherapy and will
      furnish the knowledge base of QEEG changes related to clinical variables, providing pilot
      data for a study in a larger sample. We have hypothesized that clinical response will
      correlate with changes in QEEG metrics from beginning to two weeks after treatment, and that
      QEEG parameters, different from those that predict response to pharmacotherapy, will be
      associated with response to CBT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D-17) Scores</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Hamilton Depression Rating Scale is a clinician-rated scale used to rate depression severity. The maximum score is a 50 and the minimum score is a 0, where higher scores indicate greater severity. Scores from 14 to 18 indicate moderately severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Absolute Beta Power in Channel 4</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in absolute power of the beta wave recorded from channel 4 of the EEG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Absolute Theta Power From Channel 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 1 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Relative Theta Power Channel 3</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 3 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Relative Theta Power From Channel 4</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Relative Beta Power From Channel 4</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the beetawave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the beta wave compared with the total power in the patient's EEG.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Absolute Beta Power From the Ear Channel</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in absolute power of the beta wave recorded from the ear channel of the EEG. The ear channel refers to the average of channels 3 and 4.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Relative Theta Power From Temporal Channel</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the theta wave recorded from the temporal channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The temporal channel refers to the average of channels 1 and 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Relative Theta Power From Ear Channel</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change between baseline and LOCF in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Relative Theta Power From Week 1 of the Ear Channel</measure>
    <time_frame>1 week</time_frame>
    <description>Percent change between baseline and week 1 in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Cognitive Behavioral Therapy (CBT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CBT is a manualized therapeutic treatment for depression based on principles of cognitive restructuring and behavioral changes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram or Lexapro is a Selective Serotonin Reuptake Inhibitor (SSRI) used to treat depression</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy (CBT)</intervention_name>
    <description>The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.</description>
    <arm_group_label>Cognitive Behavioral Therapy (CBT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be adults, ages 18 to 75 years.

          -  Written informed consent

          -  MDD, current according to the fourth version of the Diagnostic and Statistical Manual
             for Mental Disorders (DSM-IV)

          -  17-item Hamilton Depression Rating Scale (HAM-D-17) score of &gt; 14 at baseline.

          -  Subjects who are not currently taking any antidepressant or other psychotropic
             medications and who have been free of these medications for 4 weeks prior to screening
             visit.

        Exclusion Criteria:

          -  Women who are pregnant, lactating, or planning a pregnancy during the study.

          -  Women of child bearing potential who are not using a medically accepted means of
             contraception (to include oral contraceptive or implant, condom, diaphragm,
             spermicide, intrauterine device, tubal ligation, or a partner with vasectomy).

          -  Any uncontrolled psychiatric disorder.

          -  Current use of psychotropic medications.

          -  Psychotic features in the current episode or a history of psychotic features.

          -  Alcohol or substance abuse or dependence within the past three months.

          -  History of head trauma or seizure disorder.

          -  History of intolerance of the study medication.

          -  Failure to respond to escitalopram up to 20 mg for at least 6 weeks.

          -  Failure to respond to 2 or more adequate antidepressant trials (6 weeks or longer on a
             therapeutic dose, equivalent to fluoxetine 40mg) in the current episode.

          -  Currently enrolled in other depression-focused psychotherapy and unwilling to cease
             treatment.

          -  Subjects who, per clinical judgment, are not appropriate candidates for CBT or SSRIs.

          -  History or current diagnosis of the following DSM-IV psychiatric illness: organic
             mental disorder, schizophrenia, schizoaffective disorder, delusional disorder,
             psychotic disorders not otherwise specified, bipolar disorder, patients with mood
             congruent or mood incongruent psychotic features, patients with substance dependence
             disorders, including alcohol, active within the last 3 months.

          -  Serious suicide or homicide risk, as assessed by the evaluating clinician or a score
             of 4 on the third item of the HAM-D.

          -  Serious or unstable medical illness, including cardiovascular, hepatic, renal,
             respiratory, endocrine, neurologic or hematologic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Farabaugh, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2009</study_first_posted>
  <results_first_submitted>December 5, 2012</results_first_submitted>
  <results_first_submitted_qc>December 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2013</results_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Amy Farabaugh, PhD</investigator_full_name>
    <investigator_title>Staff psychologist</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder (MDD)</keyword>
  <keyword>Cognitive Behavioral Therapy (CBT)</keyword>
  <keyword>Escitalopram</keyword>
  <keyword>Quantitative EEG (QEEG)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was screened on January 6, 2009, and the last patient was screened on October 26, 2010. The study was completed at the Depression Clinical and Research Program at Massachusetts General Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.</description>
        </group>
        <group group_id="P2">
          <title>Escitalopram</title>
          <description>The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.</description>
        </group>
        <group group_id="B2">
          <title>Escitalopram</title>
          <description>The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Age data unavailable for 2 participants</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="14.2"/>
                    <measurement group_id="B2" value="43.3" spread="15.5"/>
                    <measurement group_id="B3" value="43.9" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age at screen was not available for 2 participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HAM-D-17) Scores</title>
        <description>The Hamilton Depression Rating Scale is a clinician-rated scale used to rate depression severity. The maximum score is a 50 and the minimum score is a 0, where higher scores indicate greater severity. Scores from 14 to 18 indicate moderately severe depression.</description>
        <time_frame>12 weeks</time_frame>
        <population>The number of participants for analysis was based on the number of participants who completed treatment (12 weeks of CBT or medication)</population>
        <group_list>
          <group group_id="O1">
            <title>Cognitive Behavioral Therapy (CBT)</title>
            <description>Patients receive twelve weekly 50-minute individual sessions of cognitive-behavioral therapy over the course of twelve weeks. Scores on the HAM-D-17 at Week 12 are the primary outcome measure.</description>
          </group>
          <group group_id="O2">
            <title>Escitalopram</title>
            <description>Patients received 10-20 mg/day of flexible-dose open-label escitalopram for 12 weeks. Scores on the HAM-D-17 at Week 12 are the primary outcome measure.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAM-D-17) Scores</title>
          <description>The Hamilton Depression Rating Scale is a clinician-rated scale used to rate depression severity. The maximum score is a 50 and the minimum score is a 0, where higher scores indicate greater severity. Scores from 14 to 18 indicate moderately severe depression.</description>
          <population>The number of participants for analysis was based on the number of participants who completed treatment (12 weeks of CBT or medication)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.64" spread="6.44"/>
                    <measurement group_id="O2" value="13.78" spread="9.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute Beta Power in Channel 4</title>
        <description>Change between baseline and LOCF in absolute power of the beta wave recorded from channel 4 of the EEG</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Beta Power in Channel 4</title>
          <description>Change between baseline and LOCF in absolute power of the beta wave recorded from channel 4 of the EEG</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0930" spread=".13602"/>
                    <measurement group_id="O2" value="-.0102" spread=".09301"/>
                    <measurement group_id="O3" value=".0683" spread=".151"/>
                    <measurement group_id="O4" value=".0056" spread=".1084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute Theta Power From Channel 1</title>
        <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 1 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Theta Power From Channel 1</title>
          <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 1 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".225" spread=".02765"/>
                    <measurement group_id="O2" value="-.0455" spread=".07683"/>
                    <measurement group_id="O3" value=".0075" spread=".0734"/>
                    <measurement group_id="O4" value=".003" spread=".0535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Relative Theta Power Channel 3</title>
        <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 3 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relative Theta Power Channel 3</title>
          <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 3 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0362" spread=".04460"/>
                    <measurement group_id="O2" value="-.0090" spread=".0859"/>
                    <measurement group_id="O3" value=".0015" spread=".02993"/>
                    <measurement group_id="O4" value=".272" spread=".06577"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Relative Theta Power From Channel 4</title>
        <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relative Theta Power From Channel 4</title>
          <description>Change between baseline and LOCF in relative power of the theta wave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG.</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0336" spread=".04428"/>
                    <measurement group_id="O2" value="-.0009" spread=".03210"/>
                    <measurement group_id="O3" value=".0076" spread=".03678"/>
                    <measurement group_id="O4" value=".0070" spread=".04429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Relative Beta Power From Channel 4</title>
        <description>Change between baseline and LOCF in relative power of the beetawave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the beta wave compared with the total power in the patient's EEG.</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relative Beta Power From Channel 4</title>
          <description>Change between baseline and LOCF in relative power of the beetawave recorded from channel 4 of the EEG. Relative power refers to the percentage of power in the beta wave compared with the total power in the patient's EEG.</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0483" spread=".03560"/>
                    <measurement group_id="O2" value=".0173" spread=".02921"/>
                    <measurement group_id="O3" value=".0063" spread=".03758"/>
                    <measurement group_id="O4" value=".0179" spread=".02929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Absolute Beta Power From the Ear Channel</title>
        <description>Change between baseline and LOCF in absolute power of the beta wave recorded from the ear channel of the EEG. The ear channel refers to the average of channels 3 and 4.</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Absolute Beta Power From the Ear Channel</title>
          <description>Change between baseline and LOCF in absolute power of the beta wave recorded from the ear channel of the EEG. The ear channel refers to the average of channels 3 and 4.</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0537" spread=".08943"/>
                    <measurement group_id="O2" value="-.0167" spread=".07461"/>
                    <measurement group_id="O3" value=".0670" spread=".14412"/>
                    <measurement group_id="O4" value="-.01401" spread=".08307"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Relative Theta Power From Temporal Channel</title>
        <description>Change between baseline and LOCF in relative power of the theta wave recorded from the temporal channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The temporal channel refers to the average of channels 1 and 2</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relative Theta Power From Temporal Channel</title>
          <description>Change between baseline and LOCF in relative power of the theta wave recorded from the temporal channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The temporal channel refers to the average of channels 1 and 2</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0182" spread=".02003"/>
                    <measurement group_id="O2" value="-.0159" spread=".03422"/>
                    <measurement group_id="O3" value=".0125" spread=".07914"/>
                    <measurement group_id="O4" value=".0027" spread=".03688"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Relative Theta Power From Ear Channel</title>
        <description>Change between baseline and LOCF in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
        <time_frame>12 weeks</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Relative Theta Power From Ear Channel</title>
          <description>Change between baseline and LOCF in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>Hz</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".0349" spread=".04440"/>
                    <measurement group_id="O2" value="-.0050" spread=".03487"/>
                    <measurement group_id="O3" value=".0046" spread=".02858"/>
                    <measurement group_id="O4" value=".0171" spread=".04103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Relative Theta Power From Week 1 of the Ear Channel</title>
        <description>Percent change between baseline and week 1 in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
        <time_frame>1 week</time_frame>
        <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
        <group_list>
          <group group_id="O1">
            <title>Non Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O2">
            <title>Responders in CBT Arm</title>
            <description>Individuals randomized to the CBT group who did respond to the CBT treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O3">
            <title>Non Responders in Medication Arm</title>
            <description>Individuals randomized to the CBT group who did not respond to the Medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
          <group group_id="O4">
            <title>Responders in Medication Arm</title>
            <description>Individuals randomized to the medication group who did respond to the medication treatment. Response defined as greater than 50% reduction in HAM D scores</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Relative Theta Power From Week 1 of the Ear Channel</title>
          <description>Percent change between baseline and week 1 in relative power of the theta wave recorded from the ear channel of the EEG. Relative power refers to the percentage of power in the theta wave compared with the total power in the patient's EEG. The ear channel refers to the average of channels 3 and 4</description>
          <population>EEG data only available for 11 participants from CBT arm and 11 participants from Medication arm</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.1809" spread="42.17256"/>
                    <measurement group_id="O2" value="8" spread="27.45993"/>
                    <measurement group_id="O3" value="7.5180" spread="29.37028"/>
                    <measurement group_id="O4" value="23.3718" spread="41.25936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cognitive Behavioral Therapy (CBT)</title>
          <description>The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.</description>
        </group>
        <group group_id="E2">
          <title>Escitalopram</title>
          <description>The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>2/16 participants reported nausea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>4/16 participants reported experiencing headaches.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>migraines</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>sweatiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>sleepiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>fidgetiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>knee aching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>syncopal episode</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>irregular menses</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Amy Farabaugh</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1629</phone>
      <email>afarabaugh@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

